多发性骨髓瘤贫血的发病机制及治疗研究进展  

Research progress on pathogenesis and treatment of anemia in multiple myeloma

作　　者：吴文忠[1] 周志刚[1] 陈亚峰[1] 张云平[1] 

机构地区：[1]宜兴市人民医院血液科,宜兴214200

出　　处：《世界临床药物》2016年第8期572-576,共5页World Clinical Drug

摘　　要：多发性骨髓瘤(MM)是一种常见的浆细胞恶性肿瘤,好发于老年人,约2/3的MM患者易并发贫血。MM贫血会随着MM病情的进展而加重,严重影响患者的生活质量。MM贫血的发生机制主要包括细胞因子(如白介素-6、肿瘤坏死因子-α和白介素-1等)抑制红系造血、促红细胞生成素(EPO)减少、反复感染及血黏度升高等。目前针对MM贫血的治疗主要包括原发病治疗、输血治疗及EPO治疗等。本文简要综述MM贫血的发病机制及目前的治疗方法,旨在为MM的诊治提供理论依据。Multiple myeloma （MM） is a common plasma cell malignancy, which occurs more in the elderly. Two thirds of MM patients are easily complicated with anemia, which increases with the progress of MM, and directly affects life quality of patients. The MM anemia pathogenesis includes cytokines （such as interleukin-6, tumor necrosis factor-α and interleukin-1） inhibiting red blood hematopoietic, erythropoietin （EPO） decreased, repeated infection and blood viscosity increased. The treatment of MM anemia mainly includes primary disease treatment, blood transfusions or EPO treatment. This review concludes the pathogenesis and treatment progress of MM anemia to provide theoretical guidance to the clinical treatment of MM anemia.

关 键 词：多发性骨髓瘤(MM) 贫血 促红细胞生成素(EPO) 

分 类 号：R733.3[医药卫生—肿瘤] R979.1[医药卫生—临床医学]